Lilly Flags Safety Risk in Compounded Zepbound Mixed With Vitamin B12

Core Viewpoint - Eli Lilly & Co. has raised concerns about the safety of its weight-loss drug Zepbound when combined with vitamin B12, highlighting potential risks from impurities found in compounded products [1][2] Group 1: Safety Concerns - The company discovered significant levels of an impurity resulting from a chemical reaction between tirzepatide and vitamin B12 in compounded products [1] - Lilly warned that patients using tirzepatide-B12 combinations from various sources may face unknown risks, including potential toxicity and immune reactions [2] - Testing revealed other critical safety issues, such as bacterial contamination and high levels of endotoxin, a toxic component [4] Group 2: Regulatory Context - Compounded medicines were initially allowed in the US due to a supply shortage during the early weight-loss injection boom, but the FDA has since declared the shortage over [3] - Despite the FDA's ruling, compounders continue to sell their products by exploiting regulatory loopholes, allowing them to customize drug formulations [3] - Lilly has urged the FDA to recall all compounded versions of its medicine that include untested additives [4] Group 3: Competitive Landscape - Eli Lilly faces competition from cheaper knock-off versions of its obesity and diabetes treatments, which bypass the rigorous regulatory approval process required for brand-name or generic drugs [2]